Contact Supplier

Contact Supplier

To get in touch with HAPILA GmbH, simply fill out the form below.

    Subscribe to Supplier

    Subscribe to Supplier


    HAPILA finds high demand for its enhanced API development and supply capabilities at CPHI Frankfurt

    news-releasesHAPILA GmbH
    December 9th 2022

    Gera, Germany: – High-potency active ingredient specialist CDMO HAPILA GmbH made a successful return to the rebranded CPHI Frankfurt worldwide pharma industry expo during November, highlighting its abilities to fill gaps in the active ingredients supply chain.

    HAPILA exhibited in collaboration with its global marketing and distribution partner Transo-Pharm Handels-GmbH at Booth D20 in Hall 11 of the Messe Frankfurt, showing its extensive portfolio of chemical synthesis development and GMP-manufacturing & analytical capabilities, for example Estriol, as well as innovative APIs such as BTZ-043 for clinical trials.

    Building relationships

    The HAPILA presence in Frankfurt was led by its CEO, Dr. Uwe Müller, assisted by Head of Development and Quality Control, Dr. Steffen Wittmann, along with Project Manager Dr. Richard Nohl, and QA specialist Kristin Kirmsse. The team’s strength meant HAPILA was able to simultaneously greet visitors to its dedicated stand area while also being present in other zones of the expo.

    “Our relationship with CPHI extends back to 2007 and it was good to be able once again to physically attend what has become out most important single event of the year once again,” commented Dr. Müller.

    “Once again this great event gave us an excellent platform to present ideal opportunities for our customers and for new interested potential partners as well as discuss the possibilities for interesting collaborations and to fathom new options,” said Dr. Müller.

    Supply chain issues

    The HAPILA CEO said there had been particularly strong interest in HAPILA’s CDMO capabilities at CPHI Frankfurt from a pharma industry experiencing acute supply security issues due to the effects of the COVID pandemic and a general trend towards reshoring production to Europe.

    “Pharmaceutical companies of all sizes and research organizations are increasingly looking for European partners to fulfil all API-related manufacturing and to help solve technical problems – both areas in which HAPILA has well-proven capabilities,” Dr. Müller explained.

    End-to-end services

    “We were able to use our three days in Frankfurt and our online CPHI presence to show that HAPILA has the high flexibility and wide technical know-how needed to solve almost any API sourcing issue,” he added.

    HAPILA was also able to present other advantages, such as its independence and agility, its experience in GMP-related development and manufacturing, with fully IMPD and ASMF certificated services for APIs, its in-house quality control unit, and its ability to offer end-to-end services from lab-scale to full-scale reactor processes.

    About HAPILA GmbH

    HAPILA GmbH is a contract developer and manufacturer (CDMO) that provides high-value services to pharma, biotech and fine chemicals client companies in the development and cGMP manufacture of active pharmaceutical ingredients (APIs).

    HAPILA is an independent company with particular experience in GMP-related development and GMP manufacturing, offering full regulated service for API (IMPD, ASMF) to very high scientific and quality assurance (QA) levels.

    It supports the development and manufacture of drug products with patented processes and in-depth experience in the API value-creation chain from synthesis through purification to particle design.

    The company’s mission is to supply exclusive products of highest quality, potency and safety in compliance with GMP and environmental protection guidelines. All HAPILA teamwork is focused on product quality and customer satisfaction.

    All HAPILA chemical synthesis is carried out at in-house at its GMP certified laboratories at Gera, Thuringia, in east-central Germany.

    When combined with purification and particle design, HAPILA’s chemical synthesis services cover the complete API value-creation chain, enabling it to be a highly efficient bridge-builder between API production and pharmaceutical end-use.

    For more information, visit:

    About CPHI Frankfurt 2022

    In its 33rd year, CPhI Worldwide has rebranded as CPHI ‘At the heart of Pharma’, continuing as the flagship European annual trade show for pharma ingredients and partner sourcing.

    CPHI Frankfurt adopted a hybrid model fusing a large physical expo with an online dimension to make networking and browsing easier and to extend the time frame of the event indefinitely.

    For 2022, CPHI Frankfurt was a three-day physical event opening November 1 at the Messe expo center in Frankfurt-am-Main, with the online exhibition opening from September 28.

    The previous ‘seven shows in one’ format was replaced by a larger number of more precisely targeted exhibition zones and online spaces, including Analytical & Lab Zone, APIs, BioProduction, CRO & Clinical Trials, Excipients, Fine Chemicals, Finished Dosage Formulations, ICSE (Outsourcing), InnoPack (Packaging), Integrated Pharma, Natural Extracts, and PMEC (Machinery and Equipment.

    CPHI Frankfurt was organised by Informa Markets with further information at:


    Click on HAPILA at CPHI Frankfurt 2022  for more information.

    HAPILA finds high demand for its enhanced API development and supply capabilities at CPHI Frankfurt

    Contact HAPILA GmbH

    Simply fill out the form below to contact HAPILA GmbH now.

    Send HAPILA GmbH a Message